Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic Inoperable Plexiform Neurofibromas

  • STATUS
    Recruiting
  • End date
    Nov 22, 2024
  • participants needed
    146
  • sponsor
    AstraZeneca
Updated on 1 December 2021

Summary

A global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas.

Description

This is a randomized, double-blind, placebo-controlled, 2 arm multicentre, global Phase III study to assess the efficacy and safety of selumetinib compared with placebo in adult participants with NF1 who have symptomatic, inoperable PN.

Details
Condition Neurofibromatosis, Plexiform Neurofibroma, von Recklinghausen's Disease, Peripheral Neuropathy
Treatment Placebo, Selumetinib
Clinical Study IdentifierNCT04924608
SponsorAstraZeneca
Last Modified on1 December 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Adults 18 years at enrollment with diagnosis of NF1 with symptomatic, inoperable PN
At least one inoperable target PN measurable by volumetric MRI analysis
Chronic target PN pain score documented for minimum period during screening period
Stable chronic PN pain medication use at enrollment
Adequate organ and marrow function

Exclusion Criteria

Confirmed or suspected malignant glioma or MPNST (optic glioma not requiring chemotherapy or radiation therapy are exempt from this exclusion)
History of malignancy except for malignancy treated with curative intent with no known active disease 5 years before the first dose of study intervention and of low potential risk for recurrence
Clinically significant cardiovascular disease, including inherited coronary disease, acute coronary syndrome within 6 months prior to enrollment, uncontrolled angina, symptomatic heart failure, cardiomyopathy, severe valvular heart disease, abnormal LVEF and uncontrolled hypertension
Ophthalmological findings/conditions including intraocular pressure > 21 mmHg, RPED/CSR or RVO
Prior exposure to MEK inhibitors
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note